Methods and compositions to inhibit symptoms associated with veisalgia
Inventors
Iversen, Jacqueline M. • Iversen, James M.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11464766-B2
Publication Date
2022-10-11
Expiration Date
Abstract
The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.
Core Innovation
The invention relates to methods and pharmaceutical compositions for inhibiting the symptoms associated with intake of alcohol. A pharmaceutical composition is administered to a subject in an effective amount prior to alcohol intake, and the composition consists of a non-steroidal anti-inflammatory drug and an H1-antihistamine. The symptoms associated with alcohol intake are inhibited by this pre-intake administration.
The non-steroidal anti-inflammatory drug is selected from aspirin, diclofenac, diflunisal, etodolac, indomethacin, ketorolac, meloxicam, nabumetone, piroxicam, salsalate, sulindac, and tolmetin, including pharmaceutically acceptable salts of any of the foregoing non-steroidal anti-inflammatory drugs. The H1-antihistamine is a non-sedating H1-antihistamine, including fexofenadine, loratadine, cetirizine, and desloratadine, as described in the provided partial content and reflected by dependent coverage.
The pharmaceutical composition can optionally include a pharmaceutical carrier, pharmaceutical excipient, and multiple additional optional components such as sweetening agents, flavoring agents, taste masking ingredients, diluents, alum, stabilizers, buffers, coloring agents, breath neutralizers, proton pump inhibitors, emulsifying agents, suspending agents, and combinations thereof. The provided partial content further describes oral/ODT tablet or lozenge-type formulations and unit-dose combinations, with the stated outcome being reduced hangover-related symptoms.
Claims Coverage
The document includes two independent claims. Together, they cover a pre-alcohol administration method using a combined NSAID plus H1-antihistamine composition, with symptom inhibition as the functional outcome.
Pre-alcohol NSAID plus H1-antihistamine symptom inhibition method
Administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists of a non-steroidal anti-inflammatory drug selected from aspirin, diclofenac, diflunisal, etodolac, indomethacin, ketorolac, meloxicam, nabumetone, piroxicam, salsalate, sulindac, tolmetin, and pharmaceutically acceptable salts thereof, and an H1-antihistamine, optionally with pharmaceutical carriers/excipients and other conventional optional components, such that the symptoms associated with the intake of alcohol are inhibited.
Pre-alcohol ibuprofen plus cetirizine composition for symptom inhibition
Administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists of about 220 mg to about 800 mg of ibuprofen and about 5 mg to 20 mg of cetirizine, optionally with pharmaceutical carriers/excipients and other conventional optional components, such that the symptoms associated with the intake of alcohol are inhibited.
The independent claims define a method in which an NSAID is combined with an H1-antihistamine and administered prior to alcohol intake, with inhibition of alcohol-associated symptoms as the intended result.
Stated Advantages
Inhibits the symptoms associated with the intake of alcohol.
Reduces hangover-related symptoms including headache/fatigue and reduced thirst, as described in the provided partial content.
Documented Applications
Methods and pharmaceutical compositions for inhibiting veisalgia (hangover) symptoms following alcohol intake, as reflected by the described pre-alcohol administration approach in the partial content.
Interested in licensing this patent?